RCG
NVS icon

Ruane, Cunniff & Goldfarb’s Novartis NVS Stock Holding History

Ruane, Cunniff & Goldfarb’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-8,674
Closed -$732K – 160
2014
Q3 		$732K Buy
+8,674
New +$702K ﹤0.01% 109

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Ruane, Cunniff & Goldfarb's NVS Position: Q4 2014 in Review

Ruane, Cunniff & Goldfarb sold out of Novartis (NVS) in Q4 2014, closing a stake of 8,674 shares — an estimated $732K sold.

Ruane, Cunniff & Goldfarb first reported a position in NVS in Q3 2014 and held it in 1 quarter. The position peaked at $732K in Q3 2014. 919 funds tracked by Wall St. Rank hold NVS as of Q4 2014.

  • Ruane, Cunniff & Goldfarb reported no remaining Novartis position as of Q4 2014 after selling out during the quarter.
  • Ruane, Cunniff & Goldfarb sold 8,674 Novartis shares in Q4 2014, an estimated $732K.
  • Ruane, Cunniff & Goldfarb first reported a position in Novartis in Q3 2014 and held it in 1 quarter.
  • Ruane, Cunniff & Goldfarb's Novartis position peaked at $732K in Q3 2014.
  • 919 funds tracked by Wall St. Rank held Novartis as of Q4 2014.

Based on Ruane, Cunniff & Goldfarb's 13F filing for Q4 2014, filed 17 Feb 2015.